Juan Manuel O'Connor, MD, MSc, Instituto Alexander Fleming, Buenos Aires, Argentina, discusses the use of circulating tumor DNA (ctDNA) as a prognostic biomarker to guide treatment decisions in colon cancer. The challenges involved in determining the clinical relevance and reliability of ctDNA in this context are highlighted. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancer Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
